MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26083808 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ilaria Leoni und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department for Life Quality Studies, University of Bologna, 47921 Rimini, Italy. Hauptthemen laut MEDLINE: MicroRNAs, Sorafenib, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bologna, Italian Association for Cancer Research, European Union.
Abstract (Originalsprache)
The approval of immunotherapy has revolutionized the management of hepatocellular carcinoma (HCC) patients. However, sorafenib remains a first-line therapeutic option for advanced patients and, in particular, for patients not eligible for immune checkpoint inhibitors, but its efficacy is limited by the onset of acquired resistance, highlighting the urgent need for predictive biomarkers. This study investigates the role of miR-22 in metabolic reprogramming and its potential as a biomarker in HCC. The analysis of miR-22 expression was performed in HCC patients and preclinical models by qPCR. Functional analyses in HCC cells evaluated GLUT1 as a direct miR-22 target. Cellular and metabolic assays evaluated the miR-22/GLUT1 axis’s role in metabolic changes, tumor aggressiveness, and sorafenib response. Circulating miR-22 was analyzed in sorafenib-treated HCC patients and rats. MiR-22 was downregulated in HCCs and associated with aggressive tumor features. Functionally, miR-22 modulated the HIF1A pathway, enhanced survival in stressful conditions, promoted a glycolytic shift, and enhanced cancer cell plasticity and sorafenib resistance via GLUT1 targeting. In addition, high serum miR-22 levels were associated with sorafenib resistance in HCC patients and rats. GLUT1 inhibition sensitized low miR-22-expressing HCC cells to sorafenib in preclinical models. These findings suggest that circulating miR-22 deserves attention as a predictive biomarker of sorafenib response. GLUT1 inhibition may represent a therapeutic strategy to combine with sorafenib, particularly in patients exhibiting high circulating miR-22 levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department for Life Quality Studies, University of Bologna, 47921 Rimini, Italy.
- Centre for Applied Biomedical Research-CRBA, University of Bologna, 40138 Bologna, Italy.
- Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.
- Department of Pharmaceutical Sciences, Università del Piemonte Orientale, 28100 Novara, Italy.
- Department of Medical and Surgical Sciences, Bologna University, 40138 Bologna, Italy.
- Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
ORCID-Profile: Giuseppe Galvani, Elisa Monti, Francesca Valenti, Marianna Moro, Camelia A Coada, Alessandro Perrone, Valeria Righi, Gloria Ravegnini, Catia Giovannini, Maurizio Baldassarre, Matteo Ravaioli, Francesco Vasuri, Fabio Piscaglia, Romana Fato, Laura Gramantieri, Christian Bergamini, Francesca Fornari
Förderung
- University of Bologna
- Italian Association for Cancer Research
- European Union
- AIRC
- European Union—NextGenerationEU
- Indena S.p.A. (Milano)
Zitieren
APA
Leoni, I., Galvani, G., Monti, E., Vianello, C., Valenti, F., Pincigher, L., Grolla, A. A., Moro, M., Coada, C. A., Perrone, A., Righi, V., Marinelli, S., Ravegnini, G., Giovannini, C., Baldassarre, M., Pariali, M., Ravaioli, M., Cescon, M., Vasuri, F., …, & Fornari, F. (2025). MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26083808
Vancouver
Leoni I, Galvani G, Monti E, Vianello C, Valenti F, Pincigher L, et al. MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26083808
BibTeX
@article{Leoni2025,
author = {Leoni, Ilaria and Galvani, Giuseppe and Monti, Elisa and Vianello, Clara and Valenti, Francesca and Pincigher, Luca and Grolla, Ambra A and Moro, Marianna and Coada, Camelia A and Perrone, Alessandro and Righi, Valeria and Marinelli, Sara and Ravegnini, Gloria and Giovannini, Catia and Baldassarre, Maurizio and Pariali, Milena and Ravaioli, Matteo and Cescon, Matteo and Vasuri, Francesco and Domenicali, Marco and Negrini, Massimo and Piscaglia, Fabio and Fato, Romana and Stefanelli, Claudio and Gramantieri, Laura and Bergamini, Christian and Fornari, Francesca},
title = {MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26083808}
}
EUVIMED